Skip to main content
Erschienen in:

09.06.2016 | Originalien

Urinary MCP-1 as a biomarker for lupus nephritis: a meta-analysis

verfasst von: MD PhD Y. H. Lee, G. G. Song

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aimed to evaluate whether urinary monocyte chemoattractant protein-1 (MCP-1) could serve as a biomarker for lupus nephritis (LN).

Methods

We performed a meta-analysis to examine the relationship between urinary MCP-1 level and LN in three comparisons: active LN versus inactive LN, active LN versus control, and inactive LN versus control.

Results

Eight studies of a total of 399 patients with LN (204 with active LN, and 195 with inactive LN) and 130 controls were available for this meta-analysis. The meta-analysis revealed that the urinary MCP-1 level was significantly higher in the active-LN group than in the inactive-LN group (standard mean difference [SMD] = 1.883, 95 % confidence interval [CI] = 0.811–2.954, p = 0.001). The meta-analysis showed that the urinary MCP-1 level was significantly higher in the active-LN group than in the control group (SMD = 3.085, 95 % CI = 1.684–4.485, p = 1.6 × 10−5). Furthermore, stratification by ethnicity showed significantly elevated urinary MCP-1 levels in the active-LN group in Caucasian, Asian, and Egyptian populations (SMD = 2.408, 95 % CI = 1.711–3.105, p < 1.0 × 10−8; SMD = 1.020, 95 % CI = 0.623–2.153, p = 4.6 × 10−7; and SMD = 7.370, 95 % CI = 1.467–2.157, p = 5.9 × 10−5, respectively). The meta-analysis indicated that the urinary MCP-1 level was also significantly higher in the inactive-LN group than in the control group (SMD = 1.812, 95 % CI = 0.628–2.996, p = 0.003).

Conclusions

The meta-analysis demonstrated that urinary MCP-1 was significantly higher in patients with active LN than in those with inactive LN and control subjects, and the patients with inactive LN showed significantly higher urinary MCP-1 levels than the controls.
Literatur
1.
Zurück zum Zitat Waldman M, Appel GB (2006) Update on the treatment of lupus nephritis. Kidney Int 70:1403–1412CrossRefPubMed Waldman M, Appel GB (2006) Update on the treatment of lupus nephritis. Kidney Int 70:1403–1412CrossRefPubMed
2.
Zurück zum Zitat Zubiria Salgado A de, Herrera-Diaz C (2012) Lupus nephritis: an overview of recent findings. Autoimmune Dis 2012:1–21. doi:10.1155/2012/849684CrossRef Zubiria Salgado A de, Herrera-Diaz C (2012) Lupus nephritis: an overview of recent findings. Autoimmune Dis 2012:1–21. doi:10.1155/2012/849684CrossRef
3.
Zurück zum Zitat Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29:313–326CrossRefPubMedPubMedCentral Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29:313–326CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Alharazy S, Kong NC, Mohd M, Shah SA, Ba’in A, Gafor AAH (2015) Urine monocyte chemoattractant protein-1 and lupus nephritis disease activity: preliminary report of a prospective longitudinal study. Autoimmune Dis 2015:1–13. doi:10.1155/2015/962046CrossRef Alharazy S, Kong NC, Mohd M, Shah SA, Ba’in A, Gafor AAH (2015) Urine monocyte chemoattractant protein-1 and lupus nephritis disease activity: preliminary report of a prospective longitudinal study. Autoimmune Dis 2015:1–13. doi:10.1155/2015/962046CrossRef
5.
Zurück zum Zitat Wada T, Furuichi K, Segawa-Takaeda C et al (1999) MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 56:995–1003CrossRefPubMed Wada T, Furuichi K, Segawa-Takaeda C et al (1999) MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 56:995–1003CrossRefPubMed
6.
Zurück zum Zitat Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I (1997) An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 186:131–137CrossRefPubMedPubMedCentral Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I (1997) An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 186:131–137CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mok CC (2010) Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010:1–11. doi:10.1155/2010/638413CrossRef Mok CC (2010) Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010:1–11. doi:10.1155/2010/638413CrossRef
8.
Zurück zum Zitat Wada T, Yokoyama H, Su SB et al (1996) Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 49:761–767CrossRefPubMed Wada T, Yokoyama H, Su SB et al (1996) Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 49:761–767CrossRefPubMed
9.
Zurück zum Zitat Ghobrial EE, El Hamshary AA, Mohamed AG, Abd El Raheim YA, Talaat AA (2015) Urinary monocyte chemoattractant protein-1 as a biomarker of lupus nephritis activity in children. Saudi J Kidney Dis Transpl 26:507–515CrossRefPubMed Ghobrial EE, El Hamshary AA, Mohamed AG, Abd El Raheim YA, Talaat AA (2015) Urinary monocyte chemoattractant protein-1 as a biomarker of lupus nephritis activity in children. Saudi J Kidney Dis Transpl 26:507–515CrossRefPubMed
10.
Zurück zum Zitat Susianti H, Iriane VM, Dharmanata S et al (2015) Analysis of urinary TGF-beta1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis. Pathophysiology 22:65–71CrossRefPubMed Susianti H, Iriane VM, Dharmanata S et al (2015) Analysis of urinary TGF-beta1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis. Pathophysiology 22:65–71CrossRefPubMed
11.
Zurück zum Zitat Rosa RF, Takei K, Araujo NC, Loduca SM, Szajubok JC, Chahade WH (2012) Monocyte chemoattractant-1 as a urinary biomarker for the diagnosis of activity of lupus nephritis in brazilian patients. J Rheumatol 39:1948–1954CrossRefPubMed Rosa RF, Takei K, Araujo NC, Loduca SM, Szajubok JC, Chahade WH (2012) Monocyte chemoattractant-1 as a urinary biomarker for the diagnosis of activity of lupus nephritis in brazilian patients. J Rheumatol 39:1948–1954CrossRefPubMed
12.
Zurück zum Zitat Xuejing Z, Jiazhen T, Jun L, Xiangqing X, Shuguang Y, Fuyou L (2012) Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol 2012:1–7. doi:10.1155/2012/359647CrossRef Xuejing Z, Jiazhen T, Jun L, Xiangqing X, Shuguang Y, Fuyou L (2012) Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol 2012:1–7. doi:10.1155/2012/359647CrossRef
13.
Zurück zum Zitat Watson L, Midgley A, Pilkington C et al (2012) Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus 21:496–501CrossRefPubMed Watson L, Midgley A, Pilkington C et al (2012) Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus 21:496–501CrossRefPubMed
14.
Zurück zum Zitat El-Shehaby A, Darweesh H, El-Khatib M et al (2011) Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 31:848–856CrossRefPubMed El-Shehaby A, Darweesh H, El-Khatib M et al (2011) Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 31:848–856CrossRefPubMed
15.
Zurück zum Zitat Noris M, Bernasconi S, Casiraghi F et al (1995) Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 73:804–809PubMed Noris M, Bernasconi S, Casiraghi F et al (1995) Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 73:804–809PubMed
16.
Zurück zum Zitat Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2010) Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus 19:703–710CrossRefPubMed Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2010) Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus 19:703–710CrossRefPubMed
17.
Zurück zum Zitat Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2010) Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis. Mol Biol Rep 37:227–234CrossRefPubMed Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2010) Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis. Mol Biol Rep 37:227–234CrossRefPubMed
18.
Zurück zum Zitat Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13CrossRefPubMedPubMedCentral Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Wells G, Shea B, O’connell D et al (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Eur J Epidemiol 25(9):603–605 Wells G, Shea B, O’connell D et al (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Eur J Epidemiol 25(9):603–605
21.
Zurück zum Zitat DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed
22.
Zurück zum Zitat Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed
24.
Zurück zum Zitat Duval S, Tweedie R (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463CrossRefPubMed Duval S, Tweedie R (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463CrossRefPubMed
25.
Zurück zum Zitat Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus. I. general overview of biomarkers and their applicability. arthritis and rheumatism. Arthritis Care Res 50:1709–1720CrossRef Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus. I. general overview of biomarkers and their applicability. arthritis and rheumatism. Arthritis Care Res 50:1709–1720CrossRef
27.
Zurück zum Zitat Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN (2005) Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 16:467–473CrossRefPubMed Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN (2005) Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 16:467–473CrossRefPubMed
Metadaten
Titel
Urinary MCP-1 as a biomarker for lupus nephritis: a meta-analysis
verfasst von
MD PhD Y. H. Lee
G. G. Song
Publikationsdatum
09.06.2016
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 4/2017
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-016-0109-z

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Podcast

Magendarminfekte: Dos and Don'ts bei Kleinkindern

Die Leitlinie zur akuten infektiösen Gastroenteritis wurde 2024 umfassend überarbeitet. Cola und Saft zur oralen Hydratation und einige Antidiarrhoika sollten vermieden werden. Von einem standardmäßigen Erregerpanel wird abgeraten. Die Hintergründe zu diesen und weiteren Empfehlungen erläutert Leitlinienkoordinator Prof. Carsten Posovszky.

Körperlich fitte Krebskranke leben länger

Krebspatienten, auch und vor allem solche in fortgeschrittenen Stadien, profitieren offenbar von guter körperlicher Verfassung. Hohe Muskelkraft und kardiorespiratorische Fitness sind laut Ergebnissen einer Metaanalyse mit geringerer Mortalität assoziiert.

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

HCL-Systeme bei Typ-1-Diabetes: Blutzuckerkontrolle besser, Risiko für Ketoazidose aber höher

Eine bessere Blutzuckerkontrolle und weniger Fälle von hypoglykämischem Koma, dafür mehr diabetische Ketoazidosen. Dieses HCL-Insulin-Therapie-Profil zeigte sich in einem Vergleich von Hybrid-Closed-Loop(HCL)- und Open-Loop-Systemen bei Typ-I-Diabetes im DPV-Register.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.